Amplitude Ventures
3 Place Ville-Marie, Suite 12350, Montreal, QC, H3B 0E7, Canada
Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Congruence Therapeutics | Mar 2026Participated | $40 MOther Equity | |
Mediar Therapeutics | Jan 2026Led | $76 MSeries B | |
Congruence Therapeutics | Sep 2025Participated | $32 MOther Equity | |
Reverb Therapeutics | Feb 2025Led | $12 MSeed | |
Fluid Biomed Inc. | Dec 2024Led | $27 MSeries A | |
Evommune | Oct 2024Participated | $115 MSeries C | |
Nomic | Sep 2024Participated | $42 MSeries B | |
Radiant Biotherapeutics | Sep 2024Led | $35 MSeries A | |
Ability biologics | Jun 2024Led | $18 MSeed | |
Ability biologics | Dec 2023Led | $12 MSeed | |
Tentarix Biotherapeutics | Sep 2023Led | $35 MSeries B | |
Evommune | Apr 2023Participated | $50 MSeries B | |
Congruence Therapeutics | Mar 2026Participated | $40 MOther Equity | |
Mediar Therapeutics | Jan 2026Led | $76 MSeries B | |
Congruence Therapeutics | Sep 2025Participated | $32 MOther Equity | |
Reverb Therapeutics | Feb 2025Led | $12 MSeed | |
Fluid Biomed Inc. | Dec 2024Led | $27 MSeries A | |
Evommune | Oct 2024Participated | $115 MSeries C | |
Nomic | Sep 2024Participated | $42 MSeries B | |
Radiant Biotherapeutics | Sep 2024Led | $35 MSeries A | |
Ability biologics | Jun 2024Led | $18 MSeed | |
Ability biologics | Dec 2023Led | $12 MSeed | |
Tentarix Biotherapeutics | Sep 2023Led | $35 MSeries B | |
Evommune | Apr 2023Participated | $50 MSeries B |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 5 | 2 |
| Series A | 4 | 4 |
| Series B | 3 | 4 |
| Series C+ | 0 | 2 |
| Other Equity | 0 | 2 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jan '20 | 1 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 1 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 1 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 2 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 1 |
| Dec '21 | 1 |
| Jan '22 | 1 |
| Feb '22 | 0 |
| Mar '22 | 1 |
| Apr '22 | 2 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 3 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 1 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 1 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 1 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 2 |
| Oct '24 | 1 |
| Nov '24 | 0 |
| Dec '24 | 1 |
| Jan '25 | 0 |
| Feb '25 | 1 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 1 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 1 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 26 |
| AI & Machine Learning | 3 |
| Marketing & Advertising | 1 |
| Data, Analytics & IT | 1 |
| Space & Frontier Tech | 1 |
| Developer Tools | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 3 |
| $10M-$25M | 7 |
| $25M-$50M | 9 |
| $50M-$100M | 4 |
| $100M-$250M | 3 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Canada | 19 |
| United States | 5 |
| Israel | 2 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Alexandria Venture Investments | 9 |
| Fonds de solidarit FTQ | 7 |
| BDC Capital | 4 |
| Investissement Québec | 4 |
| Lumira Ventures | 4 |
| OrbiMed | 3 |
| Sectoral Asset Management | 3 |
| Silver Arc Private Capital | 3 |
| Theodorus | 3 |
| Air Street Capital | 2 |
| ALS Investment Fund | 2 |
| Amgen Ventures | 2 |
| Andera Partners | 2 |
| Casdin Capital | 2 |
| Charles River Laboratories | 2 |
| Driehaus Capital Management | 2 |
| EQT Life Sciences (LSP) | 2 |
| FACIT | 2 |
| Forbion | 2 |
| Longwood Fund | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 12 | 46% |
| Participating | 14 | 54% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 7 | 58% |
| Co-led | 5 | 42% |
Team
Co-Founder & Investor
Co-Founder and Principal
Co-Founder and Partner
Principal